FDA Approves New Antibiotic for Pneumonia, Skin Infections.
The US Food and Drug Administration (FDA) yesterday gave clinicians a much-needed new weapon against tough bacterial infections by approving ceftaroline fosamil (Teflaro; Forest Laboratories) for treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin-structure infections (ABSSSI), including the notorious methicillin-resistant Staphylococcus aureus (MRSA). Ceftaroline, an injectable antibiotic, is a cephalosporin, which counter bacteria by interfering with their cell walls.
